Use of glycyrrhizin and its derivatives as RANTES inducers

(19)

(11)

EP 1 421 942 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION

(48)	Corrigendum issued on:
	02.02.2005 Bulletin 2005/05

(43)	Date of publication:
	26.05.2004 Bulletin 2004/22

(21)	Application number: 03256759.6

(22)	Date of filing: 27.10.2003

(51)	International Patent Classification (IPC)⁷: A61K 31/704, A61K 31/235, A61K 31/19, A61P 31/04, A61P 31/18, A61P 35/00

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
	Designated Extension States:
	AL LT LV MK

(30)

Priority:

29.10.2002 US 422339 P

(71)	Applicant: Minophagen Pharmaceutical Co., Ltd.
	Tokyo (JP)

(72)	Inventors:
	Kobayashi, Makiko Galveston Texas 77550 (US) Matsumoto, Hiroatsu Zama-shi Kanagawa-ken (JP) Iwata, Shigemi Yokohama-shi Kanagawa-ken (JP) Suzuki, Fujio Galveston Texas 77554 (US) Utsunomiya, Tokuichiro Yamato-shi Kanagawa-ken (JP) Takeda, Midori Setagaya-ku, Tokyo (JP)

(74)	Representative: Dealtry, Brian
	Eric Potter Clarkson, Park View House, 58 The Ropewalk Nottingham NG1 5DD Nottingham NG1 5DD (GB)

(54)	Use of glycyrrhizin and its derivatives as RANTES inducers

(57) The object of the present invention is to provide the use of glycyrrhizin and its derivatives for induction of RANTES. The present invention discloses an RANTES induction method and pharmaceutical composition for the same comprising administration of glycyrrhizin and its derivatives in an amount effective for treating or preventing decreases in infection resistance to opportunistic infections occurring in burn patients, AIDS patients, cancer patients, encephalitis patients, individuals having suffered serious injuries or undergone major surgery, or individuals subject to stress.